Changes relating to buy-back - Appendix 3D
Filed with ASX · · 3 pages · English
Earlier from CSL
- IDELVION(R) (rFIX-FP) - FDA approval
- IDELVION(R) (rFIX-FP) - CHMP recommendation
- Half Year Accounts
- Announcement of buy-back - Appendix 3C
- US FDA Accepts for Review rFVIII BLA
Later from CSL
- Appendix 4E, FY Results and Analysts Presentation
- Half Yearly Report and Accounts
- CSL Settles US Class Action and Updated Profit Guidance
- Full Year Results, Appendix 4E and Analysts Presentation
- New US$500 million Private Placement
Follow CSL into a list and get an email when it puts out news.
Follow CSL